OP Asset Management Ltd Acquires Shares of 20,869 IDEXX Laboratories, Inc. $IDXX

OP Asset Management Ltd bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the first quarter, Holdings Channel reports. The institutional investor bought 20,869 shares of the company’s stock, valued at approximately $11,726,000.

Several other hedge funds have also made changes to their positions in the business. SHP Wealth Management acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $26,000. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories during the 4th quarter worth approximately $29,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IDXX shares. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. UBS Group lowered their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Finally, Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Trading Up 1.5%

NASDAQ:IDXX opened at $549.16 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a fifty day moving average price of $559.95 and a two-hundred day moving average price of $616.34. The stock has a market capitalization of $43.32 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.